Intel
INTC
ASML Holding
ASML
Disney
DIS
Apple
AAPL
Salesforce
CRM
US Stock MarketDetailed Quotes
THTX Theratechnologies
- 1.5800
- -0.0300-1.86%
Close Mar 18 16:00 ET
- 1.5800
- 0.00000.00%
Post 20:01 ET
72.65MMarket Cap-9.29P/E (TTM)
1.6100High1.5500Low75.68KVolume1.6000Open1.6100Pre Close119.62KTurnover0.22%Turnover RatioLossP/E (Static)45.98MShares2.180052wk High-2.87P/B55.21MFloat Cap1.080052wk Low--Dividend TTM34.94MShs Float17.8400Historical High--Div YieldTTM3.73%Amplitude0.8800Historical Low1.5800Avg Price1Lot Size
Theratechnologies Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...
52
9
2
$Theratechnologies (THTX.US)$
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Wednesday, 12th March at 7:30 am
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV
Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily treatment-experienced people with multidr...
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Wednesday, 12th March at 7:30 am
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV
Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily treatment-experienced people with multidr...
3
$Theratechnologies (THTX.US)$
Groundbreaking Research Shows BMI Misses Critical Heart Risks in 43% of HIV Patients
Groundbreaking Research Shows BMI Misses Critical Heart Risks in 43% of HIV Patients
$Theratechnologies (THTX.US)$
Breakthrough: Theratechnologies HIV Treatment Matches Standard Care in Challenging Cases
Breakthrough: Theratechnologies HIV Treatment Matches Standard Care in Challenging Cases
$Theratechnologies (THTX.US)$ Benzinga· 1 min ago
Theratechnologies Presented Data From A Real-world, Observational, Registry Study Demonstrating The Efficacy And Safety Of Ibalizumab In Reducing HIV RNA To Undetectable Levels In Heavily Treatment-experienced Patients With Multidrug Resistant HIV
Theratechnologies Presented Data From A Real-world, Observational, Registry Study Demonstrating The Efficacy And Safety Of Ibalizumab In Reducing HIV RNA To Undetectable Levels In Heavily Treatment-experienced Patients With Multidrug Resistant HIV
$Theratechnologies (THTX.US)$
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
Wednesday, 26th February at 7:30 am
• Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million
• Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million
• New credit facilities' favorable interest rates and amortization schedules free up approximately $...
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
Wednesday, 26th February at 7:30 am
• Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million
• Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million
• New credit facilities' favorable interest rates and amortization schedules free up approximately $...
1
$Theratechnologies (THTX.US)$
Theratechnologies Provides Update on EGRIFTA SV® Supply
28 minutes ago, 2:05 PM PST
Via GlobeNewswire
THTX
Share
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that a shortage of EGRIFTA SV® (tesamorelin for injection) will occur at the patient level in mid-January...
Theratechnologies Provides Update on EGRIFTA SV® Supply
28 minutes ago, 2:05 PM PST
Via GlobeNewswire
THTX
Share
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that a shortage of EGRIFTA SV® (tesamorelin for injection) will occur at the patient level in mid-January...
1
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
28
9
7
$Theratechnologies (THTX.US)$
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
Tuesday, 10th December at 3:15 pm
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA) has assigned a Prescriptio...
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
Tuesday, 10th December at 3:15 pm
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA) has assigned a Prescriptio...
$Theratechnologies (THTX.US)$
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients
Preliminary evidence of dose response includes significant tumor shrinkage and one patient with complete resolution of a liver lesion
MONTREAL, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologie...
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients
Preliminary evidence of dose response includes significant tumor shrinkage and one patient with complete resolution of a liver lesion
MONTREAL, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologie...
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Best Yavo : so possibly a scalp play around 4am on $iClick Interactive Asia (ICLK.US)$ ?
KKFCNAMI : Almost at all time low for WHLR. hodl for long.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
70580865 : You seriously don’t have $D-Wave Quantum (QBTS.US)$ here a day after a paper of their quantum computer outperforming super classical computer on a real-world problem is published on Science, and when they have earnings today pre-market? What is momentum for you?
Jaguar8 OP 70580865 : Do you really know how to READ? And how dare you question my watchlist. MAKE YOUR OWN WATCHLIST!
SakataGin Jaguar8 OP : block him
View more comments...